MarketCap
Facebook
X
Telegram
Oncternal Therapeutics Income Statement 2023-2008 | ONCT
Brief overview of financial performance at Oncternal Therapeutics
The overview follows changes across a five-year period. According to figures from Oncternal Therapeutics, revenue changed from 2.5 million dollars to 785 thousand dollars over five years. The total change was −68.9%, with a CAGR of approximately −20.8%. Sales followed a declining trajectory over the five years.
EBITDA was −7.5 million dollars at the beginning and −41.7 million dollars at the end of the period (−453.2%). The operating result developed less favorably than sales. EBITDA margin moved from −299.1% to −5313.9%. Cost pressure reduced operating profitability.
Net income moved from −6.6 million dollars at the start to −39.5 million dollars at the end. Larger losses indicate rising pressure on the business.
Financial takeaway
Signs of deterioration dominate the five-year picture. The most visible risks are lower net income, limited operating profitability and limited revenue growth. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Oncternal Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
27.3 M | 2.34 M | 92.2 M | 110 M | 39.2 K | 27.4 K | 2.3 B | 618 M | 658 M | 349 M | 7.99 B | 22 B | 23.5 B | - | - | - |
Shares |
2.94 M | 2.63 M | 49.3 M | 20.3 M | 10.3 K | 3.59 K | 21.5 M | 15.7 M | 14 M | 8.18 M | 63.1 M | 62.8 M | 57.4 M | 38.9 M | - | - |
Historical Prices |
9.29 | 0.89 | 1.87 | 5.41 | 3.8 | 7.63 | 107 | 39.3 | 46.9 | 42.7 | 127 | 350 | 410 | - | - | - |
Net Income |
-39.5 M | -44.2 M | -31.3 M | -17.2 M | -34.2 M | -6.58 M | -9.28 M | -17.7 M | -18.7 M | -39.4 M | -42.1 M | -27.1 M | -33.3 M | 15.3 M | -46.3 M | - |
Revenue |
785 K | 1.49 M | 4.32 M | 3.38 M | 2.42 M | 2.52 M | - | - | - | - | - | - | 14.7 M | 60.6 M | 14.7 M | - |
Gross Profit |
- | - | - | 3.38 M | - | - | - | - | - | - | - | - | 13.7 M | - | - | - |
Operating Income |
-41.7 M | -44.9 M | -31.4 M | -17.5 M | -33.1 M | -7.59 M | -9.4 M | -25.9 M | -21.8 M | -30.3 M | -43.6 M | -49.7 M | -35.9 M | 15.1 M | -46.7 M | - |
Interest Expense |
- | - | 33 K | 317 K | -1.08 M | 1 K | 122 K | 46 K | 57 K | -259 K | 1.49 M | -19 K | 398 K | 1.36 M | 188 K | - |
EBITDA |
-41.7 M | -44.9 M | -31.4 M | -17.5 M | -33.1 M | -7.54 M | -9.35 M | -25.9 M | -21.8 M | -30.2 M | -43.2 M | -49 M | -34.9 M | 16.7 M | -44.9 M | - |
Operating Expenses |
42.5 M | 46.4 M | 35.7 M | 20.9 M | 35.5 M | 10.1 M | 9.4 M | 25.9 M | 21.8 M | 30.3 M | 43.6 M | 49.7 M | 44 M | 41.7 M | - | - |
General and Administrative Expenses |
12.7 M | 13.5 M | 11.6 M | 8.37 M | 7.29 M | 1.82 M | 2.49 M | 8.7 M | 8.23 M | 9.48 M | 11.3 M | 10.8 M | 12 M | 13.2 M | 27.8 M | - |
All numbers in USD currency
Quarterly Income Statement Oncternal Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
2.96 M | 2.96 M | 2.96 M | 2.95 M | 59 M | 58.7 M | 58.5 M | 57.5 M | 54.2 M | 50.1 M | 49.4 M | 49.4 M | 49.4 M | 49.4 K | 49.1 K | 48.8 M | 20.1 K | 16.2 K | 15.4 K | 15.4 M | 15.3 K | 6.76 K | 24.1 M | 24.1 M | 24 M | 23.3 M | 22 M | 21.5 M | 16.1 M | 16 M | 16 M | 15.7 M | 142 M | 142 M | 142 M | 14 M | 140 M | 140 M | 140 M | 109 M | 76 M | 75.4 M | 66.5 M | 63.2 M | 63.2 M | 63 M | 62.9 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 51.7 M |
Net Income |
-8.46 M | -8.56 M | -8.39 M | - | -9.86 M | -8.97 M | -11.5 M | - | -11.1 M | -11.7 M | -9.9 M | - | -9.63 M | -7.68 M | -5.95 M | - | -4.4 M | -5.54 M | -4.74 M | - | -4.89 M | -22.8 M | -5.8 M | -5.42 M | -9.43 M | -10 M | -13.6 M | -9.28 M | -8.5 M | -6.4 M | -6.25 M | -6.86 M | -6.91 M | -6.05 M | 2.11 M | -3.23 M | 34.9 M | -48 M | -2.38 M | -14.5 M | -4.94 M | -10.9 M | -8.99 M | - | -8.94 M | -12.8 M | -12.6 M | -10.7 M | 7.4 M | -10.4 M | -11.1 M | -10.7 M | -9.34 M | -10.7 M | -2.6 M |
Revenue |
494 K | 801 K | 569 K | - | 179 K | 106 K | 203 K | - | 382 K | 191 K | 746 K | - | 2.13 M | 883 K | 748 K | - | 585 K | 623 K | 578 K | - | 544 K | 674 K | 470 K | - | 329 K | 1.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.64 M | 1.83 M | - | 2.03 M | 1.64 M | 9.3 M |
Operating Income |
-8.68 M | -8.86 M | -8.78 M | - | -10.4 M | -9.54 M | -12.1 M | - | -11.3 M | -11.8 M | -9.91 M | - | -9.64 M | -7.69 M | -5.96 M | - | -4.4 M | -5.54 M | -4.75 M | - | -4.95 M | -21.6 M | -5.94 M | -5.59 M | -9.63 M | -10.2 M | -13.7 M | -9.4 M | -8.53 M | -6.44 M | -6.28 M | -6.86 M | -6.93 M | -6.06 M | -6.08 M | -5.96 M | -5.86 M | -4.96 M | -5.06 M | -5.46 M | -4.96 M | -10.9 M | -8.99 M | -9.18 M | -8.96 M | -12.8 M | -12.6 M | -12.9 M | -12.8 M | -10.4 M | -11.1 M | -12 M | -9.37 M | -10.7 M | -2.44 M |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 K | 13 K | 13 K | - | 1 K | 1 K | 139 K | 171 K | 196 K | 143 K | 131 K | 122 K | 27 K | 40 K | 27 K | - | 13 K | 5 K | 28 K | -4 K | 9 K | 25 K | 27 K | -284 K | 21 K | 2 K | 2 K | 1.39 M | 23 K | 21 K | 55 K | -33 K | -47 K | 53 K | 8 K | 66 K | 23 K | 7 K | 302 K |
EBITDA |
-8.68 M | -8.86 M | -8.78 M | - | -10.4 M | -9.54 M | -12.1 M | - | -11.3 M | -11.8 M | -9.91 M | - | -9.64 M | -7.69 M | -5.96 M | - | -4.4 M | -5.54 M | -4.75 M | - | -4.95 M | -21.6 M | -5.93 M | -5.59 M | -9.59 M | -10.1 M | -13.7 M | -9.4 M | -8.5 M | -6.42 M | -6.27 M | -6.86 M | -6.91 M | -6.05 M | -6.08 M | -5.96 M | -5.83 M | -4.93 M | -5.04 M | -5.46 M | -4.87 M | -10.9 M | -8.96 M | -9.18 M | -8.63 M | -12.6 M | -12.5 M | -12.9 M | -12.2 M | -10 M | -10.9 M | -12 M | -8.55 M | -10.1 M | -2.12 M |
Operating Expenses |
9.18 M | 9.66 M | 9.35 M | - | 10.6 M | 9.65 M | 12.3 M | - | 11.7 M | 12 M | 10.7 M | - | 11.8 M | 8.57 M | 6.71 M | - | 4.98 M | 6.16 M | 5.33 M | - | 5.49 M | 22.3 M | 5.94 M | 5.59 M | 9.63 M | 10.2 M | 13.7 M | 9.4 M | 8.53 M | 6.44 M | 6.28 M | 6.86 M | 6.93 M | 6.06 M | 6.08 M | 5.96 M | 5.86 M | 4.96 M | 5.06 M | 5.46 M | 4.96 M | 10.9 M | 8.99 M | 9.18 M | 8.96 M | 12.8 M | 12.6 M | 12.9 M | 12.8 M | 11.6 M | 12.4 M | 12 M | 10.9 M | 10.6 M | 10.5 M |
General and Administrative Expenses |
2.73 M | 3.05 M | 3.29 M | - | 3.09 M | 3.07 M | 3.32 M | - | 3.26 M | 3.22 M | 3.68 M | - | 2.8 M | 3.38 M | 2.79 M | - | 1.93 M | 2.34 M | 2.63 M | - | 2.38 M | 1.62 M | 3.51 M | 2.35 M | 2.16 M | 2.2 M | 2.69 M | 2.49 M | 2.62 M | 2 M | 2.09 M | 2.28 M | 2.31 M | 2 M | 2.11 M | 2.08 M | 2.04 M | 2 M | 2.11 M | 2.2 M | 1.59 M | 3.05 M | 2.63 M | 3.09 M | 2.48 M | 2.68 M | 3.02 M | 2.86 M | 3 M | 2.59 M | 2.81 M | 3.14 M | 2.9 M | 4.47 M | 3.2 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Oncternal Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
